Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim (AMG 531) in Low/Intermediate-1 Risk MDS Receiving Lenalidomide
NCT00418665Phase 2Completed
- Sponsor
- Amgen
- Start
- Dec 2006
- Primary completion
- Mar 2009
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial of romiplostim in myelodysplastic syndrome (MDS) and Thrombocytopenia (5 arms), sponsored by Amgen. Primary endpoint: Occurrence of a Clinically Significant Thrombocytopenic Event at 16 weeks. Started Dec 2006; status: completed.
02
Drugs
romiplostim
03
Conditions
myelodysplastic syndrome (MDS)Thrombocytopenia
Beyond the preview
Go deeper on NCT00418665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00418665.